RE:RE:RE:Shareholder value???Tencents wrote: In addition to above we should take into consideration aezs management comments in its financial statements which states aezs expects to make significant losses for the foreseeable future
this probably meabb nes the cash on hand will be eaten up by end 2025 and tax losses will not be used in the short to medium term
Here's what AEZS's 6-K filing says:
"We also believe that our existing cash on hand will be sufficient to fund our anticipated operating and capital expenditure requirements beyond the next 12 months and through 2025." AEZS's existing US$38.8 million cash was expected to last through 2025. That likely doesn't take into account potential licensing payments. Strongbridge paid US$24 million plus was to pay an anticipated US$5 million for pediatric approval plus 70% of pediatric trial costs to license the test. AEZS has also talked about potentially licensing other programs like AIM Biologicals. CZO also has cash on hand and its main client is expected to return. CZO has a history of profitability. There are also dry powder formulations of CZO's active ingredients about to be launched with Symrise. AEZS's capital is also to fully fund near-term revenue generating opportunities further potentially increasing the runway. CZO's PGX, wound healing, and avenanthramide deals can also come with significant upfront and milestone payments. There are also opportunities to streamline the cost structure combining both companies by dropping the TSX-V listing, reducing the collective number of Board members, having one CFO and person in charge of business development and by having only one set of IR costs.
"The combination is attractive for shareholders of both companies, as it is expected to create a long-term sustainable business..." news release